Skip to main content
Veterinary Medicines

Finadyne vet. 50 mg/ml Injektionsvätska, suspension

Authorised
  • Flunixin meglumine

Product identification

Medicine name:
Finadyne vet. 50 mg/ml Injektionsvätska, suspension
Active substance:
  • Flunixin meglumine
Target species:
  • Horse
  • Cattle
  • Pig
Route of administration:
  • Intramuscular use
  • Intravenous use

Product details

Active substance and strength:
  • Flunixin meglumine
    83.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Horse
      • Meat and offal
        7
        day
      • Meat and offal
        1
        day
    • Cattle
      • Milk
        1
        day
      • Meat and offal
        4
        day
      • Meat and offal
        7
        day
    • Pig
      • Meat and offal
        18
        day
  • Intravenous use
    • Horse
      • Meat and offal
        1
        day
      • Meat and offal
        7
        day
    • Cattle
      • Milk
        1
        day
      • Meat and offal
        7
        day
      • Meat and offal
        4
        day
    • Pig
      • Meat and offal
        18
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QM01AG90
Authorisation status:
  • Valid
Authorised in:
  • Sweden
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Trirx Segre
Responsible authority:
  • Swedish Medical Products Agency
Authorisation number:
  • 10659
Date of authorisation status change:

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Swedish (PDF)
Published on: 26/04/2022

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Swedish (PDF)
Published on: 26/04/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."